About: Cem Akin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cem Akin Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0001-6301-4520)

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) 연구원 (ko) ricercatore (it) গবেষক (bn) 研究者 (ja) ഗവേഷകൻ (ml) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq) onderzoeker (nl) researcher (ORCID 0000-0001-6301-4520) (en)
rdfs:label	Cem Akin (en) Cem Akin (es) Cem Akin (nl) Cem Akin (sl) Cem Akin (ast)
skos:prefLabel	Cem Akin (en) Cem Akin (es) Cem Akin (nl) Cem Akin (sl) Cem Akin (ast)
name	Cem Akin (en) Cem Akin (es) Cem Akin (nl) Cem Akin (sl) Cem Akin (ast)
given name	wds:Q42415677-9ED77513-AB0D-48B9-BEAA-1544D0F78D79
given name	Cem
instance of	wds:Q42415677-AC3FE8CD-D34F-4D66-8EDB-A37A2FAD4788
instance of	Homo sapiens
occupation	wds:Q42415677-CCE56C48-F864-4142-AE2C-2CB6BAE9B50E
employer	wds:Q42415677-0B553BA9-A7A7-4DE8-A8AE-893AFCC02263 wds:Q42415677-A9A3DEB9-EF93-4CA2-8C59-900F911BE25C wds:Q42415677-C6116384-8BEF-4158-9C49-55B8A5042ECF wds:Q42415677-F53B3E4C-76A5-4457-8340-783E4E2DD55E
NUKAT ID	wds:Q42415677-DC49B8FE-9AA6-4446-998F-53FD6D9D99A0
sex or gender	wds:Q42415677-2F28BC91-6FB1-4A01-BA4B-5AC1B370E74C
ISNI	wds:Q42415677-59CD1897-E989-4615-968B-41B684483933
VIAF ID	wds:Q42415677-1D132F39-C67B-49DC-BE78-FDE2C4E1E5B0
GND ID	wds:Q42415677-3fc4375c-2e53-4f05-97fd-e2062e08babd
educated at	wds:Q42415677-B48F869A-358B-4F27-A8E2-4359648DCA4F
family name	wds:Q42415677-426299EE-6668-4466-9A74-B5A4BEBE0FEF
WorldCat Identities ID (superseded)	wds:Q42415677-455A33CC-D996-4BC4-A4CC-8900327DBDD8
VIAF ID	http://viaf.org/viaf/311258260
GND ID	https://d-nb.info/gnd/1052571778
occupation	researcher
employer	National Institutes of Health Brigham and Women's Hospital Harvard Medical School University of Michigan
NUKAT ID	n2007116496
sex or gender	male
ISNI	0000000119886516
VIAF ID	311258260
GND ID	1052571778
educated at	Istanbul University
family name	Akin
WorldCat Identities ID (superseded)	lccn-no2011069358
ORCID iD	wds:Q42415677-89661698-C777-413A-9AD1-6427EFDFB9D6
ORCID iD	https://orcid.org/0000-0001-6301-4520
ORCID iD	0000-0001-6301-4520
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q42415677
is author of	Diagnostic criteria and classification of mastocytosis in 2014. Mast Cells, Mastocytosis, and Related Disorders The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria Inhibition of murine splenic T lymphocyte proliferation by 2-deoxy-D-glucose-induced metabolic stress Current options in the treatment of mast cell mediator-related symptoms in mastocytosis Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Tryptase is not cleared by the kidneys into the urine. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal Mastocytosis and allergy. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal Mast cell proliferative disorders: current view on variants recognized by the World Health Organization International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. How I treat patients with advanced systemic mastocytosis. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software